Form 8-K · Current Report · Filed 2026-03-09
Ionis Pharmaceuticals Announces Board Member Retirements and New Appointment
Ionis Pharmaceuticals, Inc. announced on March 9, 2026, the retirements of two long-standing board members, B. Lynne Parshall and Joseph H. Wender, effective at the end of their terms in June 2026. Parshall, who previously served as Chief Operating Officer and Chief Financial Officer, and Wender, the Lead Independent Director, are stepping down after decades of service. The company also announced the appointment of Peter N. Reikes to the Board, effective June 4, 2026. Reikes, a former Ionis board member and senior advisor to the FDA, brings extensive financial and industry expertise. The transitions underscore Ionis' commitment to effective governance and strategic leadership.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-26-008340
- CIK
- 0000874015
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$74.04
Next session
+2.2%
Since filing
-30.1%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.